Blog

Recently, the Probiotic Spore Research Center – ANABIO R&D Co., Ltd. collaborated with Hanoi Obstetrics and Gynecology Hospital to conduct the study “Evaluation of the Supportive Efficacy of Bacillus Probiotic Spores (LiveSpo^® X-SECRET) in the Treatment of Vaginitis.” The study, led by MSc. Dr. Nguyen Canh Chuong – Director of the Training and Direction Center, Hanoi Obstetrics and Gynecology Hospital, was highly evaluated and officially approved with an “Excellent” rating by the hospital’s review committee on April 26, 2025.
This collaboration marks an important milestone in the application of vaginal-spraying probiotics for supporting the treatment of gynecological diseases in general, offering a sustainable, safe solution while reducing the overuse of antibiotics and antifungal agents in vaginitis management.

This is the first study in the world to demonstrate the safety and outstanding efficacy of an intravaginal Bacillus spore probiotic spray in supporting the treatment and reduction of recurrent vaginitis symptoms in patients with bacterial vaginosis and sexually transmitted infections (STIs). After 28 days of LiveSpo^® X-SECRET use combined with standard treatment regimens, the data showed:

• A 5.7-fold reduction in symptoms of inflammation, itching, abnormal vaginal odor, and abnormal vaginal discharge compared to baseline. Notably, the improvement in itching was 3-fold higher, and the improvement in multi-symptom reduction (≥3 symptoms) was 6-fold higher compared to the control group (standard treatment combined with physiological saline spray), contributing to effective symptom control and reduction of recurrence after completing the 7–10 day course of antibiotics/antifungals.
• A 275-fold decrease in Gardnerella vaginalis load and a 2.1-fold increase in Lactobacillus relative abundance compared to the control group, supporting natural restoration of the vaginal microbiota following antibiotic/antifungal therapy.
• A 43–60% reduction in pro-inflammatory cytokines (IL-1β and IL-8) and a 66% increase in vaginal IgA levels compared to the control group, strengthening the local immune barrier and reducing the risk of recurrence.

A key highlight of this study is that LiveSpo^® X-SECRET not only rapidly improved clinical symptoms but also helped reduce inflammatory markers and restore the vaginal microbiota, providing a robust foundation for natural and sustainable prevention of vaginitis recurrence. The study was highly evaluated by the review committee for its practical applicability and excellent safety profile. LiveSpo^® X-SECRET is potential as an effective supportive solution in gynecological care, contributing to a shift in the management of vaginitis and reducing dependence on antibiotics and antifungal medications

On the morning of February 10, 2025, the Spobio Research Center was honored to welcome Mrs. Isabelle Ducellier, the former CEO of Biogaia, for a visit and consultation regarding the potential development of probiotic products for the international market. This meeting provided a valuable opportunity to share ANABIO R&D’s research advancements and receive expert insights from a leading specialist in the field.

The 60-minute exchange left a profound impression on Mrs. Isabelle Ducellier, owing to the outstanding research conducted by the R&D laboratory. The collaborations with prestigious institutions, including the Central Pediatric Hospital, Thai Binh University of Medicine and Pharmacy, and the National Institute of Nutrition, have contributed to documenting the tangible benefits of probiotics in supporting the treatment of respiratory, digestive, and various other health conditions.

During the meeting, the research team presented their flagship probiotic products: PregMom, KID, Dia30, Colon, Clausy, Navax, and X-secret. These products have demonstrated exceptional efficacy in clinical trials and have been featured in renowned scientific journals such as Nature Scientific Reports and ASM. Notable findings include:

LiveSpo Navax effectively alleviates symptoms of ARTI caused by RSV while reducing viral load, offering a simple, cost-effective treatment approach for viral infections in general.

LiveSpo Colon significantly improves symptoms of chronic intestinal inflammation, including colitis, diarrhea, and constipation, while enhancing inflammatory markers and quality of life after 30 days of treatment. These improvements have been documented through comparative colonoscopy images from before and after product use.

LiveSpo Clausy regulates inflammation through the Th17 mechanism and has shown particularly promising results in reducing the duration of prolonged diarrhea in children aged 3-24 months. This contributes to reducing antibiotic use, protecting gut microbiota, and promoting healthier growth in children.

LiveSpo X-secret effectively alleviates symptoms of STDs, reduces pathogenic bacterial load, and improves the vaginal microbiota.

LiveSpo DIA30 has demonstrated remarkable effectiveness in treating prolonged diarrhea in children by reducing inflammation and improving gut microbiota without requiring antibiotics.

LiveSpo KIDS and LiveSpo PREG-MOM effectively alleviate constipation and malnutrition in children while strengthening immune systems and restoring gut microbiota.

Significantly, all ANABIO probiotic products have proven safe, with no reported side effects in clinical studies. This evidence demonstrates the effectiveness of probiotics in reducing antibiotic treatment duration, aligning with ANABIO R&D’s overarching goal: “For a future without antibiotics.”

In addition to the achievements, Mrs. Isabelle Ducellier was particularly impressed by the community-focused vision that ANABIO’s founder has instilled in every member of the research team. The unity, relentless creativity, and determination to overcome challenges in completing each study clearly reflect their shared goal: to benefit public health, with a particular focus on children’s health.

This meeting not only provided an opportunity for the Spobio Research Center to showcase its scientific accomplishments to an international expert but also served as a testament to ANABIO R&D’s commitment to LiveSpo Pharma’s vision: “For a future without antibiotics.”

Here are some pictures from the tour

The Spobiotic Research Center (Spobio Center), ANABIO R&D participated in the Dental Exhibition & Congress 2024 (VNU DEC 2024), held on November 22–23, 2024, at Vietnam National University, Hanoi. With the theme “Education and Practice in Odonto-Stomatology”,  VNU DEC 2024 brought together hundreds of leading dental experts from Vietnam and around the world. The conference was organized in collaboration with Operation Smile, US, to commemorate 35 years of its operations in Vietnam.

Representing the Spobio Center, three staff members, along with the LiveSpo Pharma, actively presented innovative probiotic spore products. Highlights included LiveSpo Navax – the world’s first respiratory probiotic – and LiveSpo^® Smile CARE – a pioneering probiotic solution for comprehensive oral care.

With Bacillus spores as its primary component, LiveSpo^® Smile CARE offers a holistic approach to oral health. The product not only cleanses the oral cavity, prevents cavities and gingivitis, and inhibits bacterial plaque formation – resulting in stronger teeth – but also helps balance the natural oral microbiome. This is recognized as a significant advancement, paving the way for modern dentistry without relying on antibiotics.

The LiveSpo Pharma booth at VNU DEC 2024 attracted considerable attention and received positive feedback from dental professionals. These responses not only reinforced the company’s pioneering position in applying probiotic spore technology but also underscored its commitment to improving community health, striving for “a future without antibiotics”.

From October 31st to November 2nd, 2024, the Spobiotic Research Center, ANABIO R&D, participated in the 25th National Pediatrics Conference in Hue City entiled “From Science to Policy and Practice.” The conference is a prestigious scientific forum, gathering leading experts from Vietnam and abroad to share the latest advancements in pediatrics.

At the conference, Dr. Dang Thuy Ha, MD, PhD, Deputy Head of the Gastroenterology Department at the National Children’s Hospital, presented the report “Characteristics of Gut Microbiota and Treatment Outcomes for Persistent Diarrhea at the National Children’s Hospital.” This research was conducted in collaboration between the doctors of the National Children’s Hospital and the Spobiotic Research Center, ANABIO R&D. The report highlighted positive results in shortening treatment duration and increasing the effectiveness of managing persistent diarrhea in children by combining conventional treatments with water-based probiotic Bacillus spore products such as LiveSpo CLAUSY (Bacillus clausii, 2 billion CFU/5 mL) and LiveSpo DIA30 (Bacillus subtilis, Bacillus clausii, Bacillus coagulans, 5 billion CFU/5 mL). These products have been recognized as promising solutions in treating prolonged diarrhea, contributing to reduced antibiotic use in children. Findings from the study were published in Nature Scientific Reports in March 2024, providing further scientific support for optimizing treatment protocols for children with prolonged diarrhea.

The conference also featured participation from numerous health administrators and leaders from healthcare facilities across the country, offering an opportunity for a comprehensive evaluation of issues in pediatrics to develop and refine appropriate health policies. Contributions at the conference not only aim to enhance the quality of child healthcare but also lay the foundation for sustainable development of Vietnam’s healthcare sector in pediatrics. This information serves as valuable updates for scientists of the Spobiotic Research Center, ANABIO R&D, to generate ideas for probiotic product development, aligned with the mission of “a future without antibiotics.”